Vol 9, No 5 (2020)
Research paper
Published online: 2020-08-22

open access

Page views 559
Article views/downloads 531
Get Citation

Connect on Social Media

Connect on Social Media

A real-world retrospective evaluation of glycaemic control and weight loss in patients with type 2 diabetes mellitus treated with canagliflozin 100 mg and canagliflozin 300 mg in an Indian setting

Poulomi Mukherjee1, Soumyabrata Roychowdhury2, Anirban Majumder2
Clin Diabetol 2020;9(5):300-305.

Abstract

Background. Canagliflozin is a sodium glucose co- -transporter 2 (SGLT2) inhibitor that improves glycaemia in patients with type 2 diabetes mellitus (T2DM) by enhancing urinary glucose excretion (UGE). Indian data regarding comparative efficacy of canagliflozin 300 mg over canagliflozin 100 mg in reduction of body weight are scanty. Objectives. To evaluate and compare the efficacy of canagliflozin 100 mg versus canagliflozin 300 mg regarding loss of body weight retrospectively, in patients with T2DM inadequately controlled with other antihypergycaemic agents (AHA) in a real world setting in India. Methods. T2DM patients inadequately controlled (HbA1c > 8.5%) with diet, exercise and AHA who were prescribed canagliflozin 100 mg (n = 62) or canagliflozin 300 mg (n = 36) once daily, between May 2016 to May 2019 and were followed for at least 20 weeks, are included in the analysis. Changes in blood pressure and glycaemic parameters and body weight are studied. Results. Results show that addition of canagliflozin 100 and 300 mg provided statistically significant improvements in glycaemic control associated with weight loss. However no superiority of canagliflozin 300 mg to canagliflozin 100 mg is established. Conclusion. The present study shows that addition of canagliflozin 300 mg has no advantage over canagliflozin 100 mg on body weight when added on existing therapy with other AHA.

Article available in PDF format

View PDF Download PDF file

References

  1. Prasanna Kumar KM, Ghosh S, Canovatchel W, et al. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2017; 21(1): 196–209.
  2. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669–2701.
  3. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014; 8: 1335–1380.
  4. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011; 91(2): 733–794.
  5. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012; 14(6): 539–545.
  6. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012; 7(2): e30555.
  7. Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010; 53(17): 6355–6360.
  8. Rosenstock J, Aggarwal N, Polidori D, et al. Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35(6): 1232–1238.
  9. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011; 13(7): 669–672.
  10. INVOKANA® (Canagliflozin) Tablets. Highlights of Prescribing Information; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf [Last accessed on September 22 2019].
  11. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56(12): 2582–2592.
  12. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36(9): 2508–2515.
  13. Cefalu W, Leiter L, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896): 941–950.
  14. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4): 372–382.
  15. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36(8): 2154–2161.
  16. Bays HE, Weinstein R, Law G, et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014; 22(4): 1042–1049.
  17. Das, A K and Sahay, B K and Seshiah et al. Indian National Consensus Group: National Guidelines on Initiation and Intensification of Insulin Therapy with Premixed Insulin Analogs. Available from: http://mdrf-eprints.in/868/[Last accessed on September 22 2019].
  18. World Health Organization.Body mass index – BMI. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bm [Last accessed on September 22 2019].
  19. Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013; 67(12): 1267–1282.
  20. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012; 35(4): 731–737.
  21. Klein S, Burke LE, Bray GA, et al. American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004; 110(18): 2952–2967.
  22. Stein P, Berg JK, Morrow L, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism. 2014; 63(10): 1296–1303.
  23. Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012; 28(7): 1167–1171.
  24. Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012; 28(7): 1173–1178.